These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22999447)

  • 1. Certificate of need regulations and the diffusion of intensity-modulated radiotherapy.
    Jacobs BL; Zhang Y; Skolarus TA; Wei JT; Montie JE; Schroeck FR; Hollenbeck BK
    Urology; 2012 Nov; 80(5):1015-20. PubMed ID: 22999447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Certificate of need legislation and the dissemination of robotic surgery for prostate cancer.
    Jacobs BL; Zhang Y; Skolarus TA; Wei JT; Montie JE; Schroeck FR; Hollenbeck BK
    J Urol; 2013 Jan; 189(1):80-5. PubMed ID: 23164388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managed care and the diffusion of intensity-modulated radiotherapy for prostate cancer.
    Jacobs BL; Zhang Y; Skolarus TA; Wei JT; Montie JE; Schroeck FR; Hollenbeck BK
    Urology; 2012 Dec; 80(6):1236-42. PubMed ID: 23206767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Certificate of need programs, intensity modulated radiation therapy use and the cost of prostate cancer care.
    Khanna A; Hu JC; Gu X; Nguyen PL; Lipsitz S; Palapattu GS
    J Urol; 2013 Jan; 189(1):75-9. PubMed ID: 23164382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Certificate of need regulations and the diffusion of intensity-modulated radiotherapy.
    Penson DF
    J Urol; 2013 Oct; 190(4):1250-1. PubMed ID: 24029317
    [No Abstract]   [Full Text] [Related]  

  • 6. Association of State Certificate of Need Regulation With Procedural Volume, Market Share, and Outcomes Among Medicare Beneficiaries.
    Yuce TK; Chung JW; Barnard C; Bilimoria KY
    JAMA; 2020 Nov; 324(20):2058-2068. PubMed ID: 33231664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Certificate of need regulations and use of coronary revascularization after acute myocardial infarction.
    Popescu I; Vaughan-Sarrazin MS; Rosenthal GE
    JAMA; 2006 May; 295(18):2141-7. PubMed ID: 16684984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managed care and the dissemination of robotic prostatectomy.
    Zhang Y; Hollenbeck BK; Schroeck FR; Jacobs BL
    Surg Innov; 2014 Dec; 21(6):566-71. PubMed ID: 25049319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer.
    Jacobs BL; Yabes JG; Lopa SH; Heron DE; Chang CH; Schroeck FR; Bekelman JE; Kahn JM; Nelson JB; Barnato AE
    Cancer; 2017 Aug; 123(15):2945-2954. PubMed ID: 28301689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensity modulated radiation therapy replaces 3-dimensional conformal radiotherapy as prostate cancer treatment.
    Elliott SP; Adejoro OO; Konety BR; Jarosek SL; Dusenbery KE; Virnig BA
    J Urol; 2012 Apr; 187(4):1253-8. PubMed ID: 22335868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health systems agency and state health planning and development agency reviews; certificate of need programs--PHS.
    Fed Regist; 1985 Jan; 50(9):2008-20. PubMed ID: 10270031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality in Medicare beneficiaries following coronary artery bypass graft surgery in states with and without certificate of need regulation.
    Vaughan-Sarrazin MS; Hannan EL; Gormley CJ; Rosenthal GE
    JAMA; 2002 Oct; 288(15):1859-66. PubMed ID: 12377084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse.
    Jacobs BL; Zhang Y; Skolarus TA; Hollenbeck BK
    Health Aff (Millwood); 2012 Apr; 31(4):750-9. PubMed ID: 22492892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity.
    Yu JB; Soulos PR; Herrin J; Cramer LD; Potosky AL; Roberts KB; Gross CP
    J Natl Cancer Inst; 2013 Jan; 105(1):25-32. PubMed ID: 23243199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer.
    Vora SA; Wong WW; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
    J Urol; 2013 Aug; 190(2):521-6. PubMed ID: 23415964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Public Health Service--health systems agencies and state health planning and development agencies; certificate of need reviews. Notice regarding certificate of need programs.
    Fed Regist; 1980 Feb; 45(37):12174-85. PubMed ID: 10245320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of regulation, competition, and ownership on mortality rates among hospital inpatients.
    Shortell SM; Hughes EF
    N Engl J Med; 1988 Apr; 318(17):1100-7. PubMed ID: 3127713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends during 1993-2004 in the availability and use of revascularization after acute myocardial infarction in markets affected by certificate of need regulations.
    Vaughan Sarrazin MS; Bayman L; Cram P
    Med Care Res Rev; 2010 Apr; 67(2):213-31. PubMed ID: 19822880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of clinical outcomes between three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer.
    Shimizuguchi T; Nihei K; Okano T; Machitori Y; Ito K; Karasawa K
    Int J Clin Oncol; 2017 Apr; 22(2):373-379. PubMed ID: 27778117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.